Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Morrissey

Showing results (1-10 of 265) with videos related to

Pageof 27
Sort By:
The New England Journal of Medicine|January 25, 2013
A different model--medical care in CubaEdward W Campion, Stephen Morrissey
The New England Journal of Medicine|November 18, 2024
NEJM at AHA - Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon DiseaseEric J Rubin, Jane Leopold, Stephen Morrissey
The New England Journal of Medicine|September 3, 2024
NEJM at ESC - Beta Blocker Interruption or Continuation with Prior Myocardial InfarctionEric J Rubin, Jane Leopold, Stephen Morrissey
The New England Journal of Medicine|September 3, 2024
NEJM at ESC - Vutrisiran in Patients with Transthyretin Amyloidosis with CardiomyopathyEric J Rubin, Jane Leopold, Stephen Morrissey
The New England Journal of Medicine|September 3, 2024
NEJM at ESC - Finerenone in Heart Failure for Mildly Reduced or Preserved Ejection FractionEric J Rubin, Jane Leopold, Stephen Morrissey
The New England Journal of Medicine|November 18, 2024
NEJM at AHA - Routine Spironolactone in Acute Myocardial InfarctionEric J Rubin, Jane Leopold, Stephen Morrissey
The New England Journal of Medicine|November 18, 2024
NEJM at AHA - Catheter Ablation or Antiarrhythmic Drugs for Ventricular TachycardiaEric J Rubin, Jane Leopold, Stephen Morrissey
The New England Journal of Medicine|November 18, 2024
NEJM at AHA - Intensive Blood-Pressure Control in Patients with Type 2 DiabetesEric J Rubin, Jane Leopold, Stephen Morrissey
The New England Journal of Medicine|November 18, 2024
NEJM at AHA - CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR CardiomyopathyEric J Rubin, Jane Leopold, Stephen Morrissey
The New England Journal of Medicine|September 3, 2024
NEJM at ESC - Asundexian versus Apixaban in Patients with Atrial FibrillationEric J Rubin, Jane Leopold, Stephen Morrissey
Pageof 27

Showing results (1-10 of 265) with videos related to

Sort By:
Pageof 27
The New England Journal of Medicine|January 25, 2013
A different model--medical care in CubaEdward W Campion, Stephen Morrissey
The New England Journal of Medicine|November 18, 2024
NEJM at AHA - Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon DiseaseEric J Rubin, Jane Leopold, Stephen Morrissey
The New England Journal of Medicine|September 3, 2024
NEJM at ESC - Beta Blocker Interruption or Continuation with Prior Myocardial InfarctionEric J Rubin, Jane Leopold, Stephen Morrissey
The New England Journal of Medicine|September 3, 2024
NEJM at ESC - Vutrisiran in Patients with Transthyretin Amyloidosis with CardiomyopathyEric J Rubin, Jane Leopold, Stephen Morrissey
The New England Journal of Medicine|September 3, 2024
NEJM at ESC - Finerenone in Heart Failure for Mildly Reduced or Preserved Ejection FractionEric J Rubin, Jane Leopold, Stephen Morrissey
The New England Journal of Medicine|November 18, 2024
NEJM at AHA - Routine Spironolactone in Acute Myocardial InfarctionEric J Rubin, Jane Leopold, Stephen Morrissey
The New England Journal of Medicine|November 18, 2024
NEJM at AHA - Catheter Ablation or Antiarrhythmic Drugs for Ventricular TachycardiaEric J Rubin, Jane Leopold, Stephen Morrissey
The New England Journal of Medicine|November 18, 2024
NEJM at AHA - Intensive Blood-Pressure Control in Patients with Type 2 DiabetesEric J Rubin, Jane Leopold, Stephen Morrissey
The New England Journal of Medicine|November 18, 2024
NEJM at AHA - CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR CardiomyopathyEric J Rubin, Jane Leopold, Stephen Morrissey
The New England Journal of Medicine|September 3, 2024
NEJM at ESC - Asundexian versus Apixaban in Patients with Atrial FibrillationEric J Rubin, Jane Leopold, Stephen Morrissey
Pageof 27